The Medical Device Business Journal — Medical Device News & Articles | MassDevice
Five major shareholders dumped more than 300,000 shares of C.R. Bard Inc. (NYSE:BCR) during the med-tech maker’s third quarter.
Capital Fund Management, Contravisory Investment Management, Public Employees Retirement Assn. of Colorado, Texas Permanent School Fund and Santa Fe Partners cumulatively sold 324,739 shares for roughly $11.8 million between June 30 and Sept. 30, according to SEC filings.
The U.S. Supreme Court heard oral arguments this week in a case that could have wide-reaching implications for health care: Whether medical patents should be allowed.
At issue is the specter of doctors being sued for patent infringement based on treatment decisions derived from the scientific research underpinning the patent.
Wall Street investors rebounded from the jolt delivered by the Centers for Medicare & Medicaid Services last week, regaining most of the value lost after the agency announced stiffer rules for its coverage of some medical procedures.
The new pre-reimbursement review program will ask doctors to provide up-front justification for certain medical equipment and types of claims. Set to launch in 11 states next month, it will flip the reimbursement system from the agency’s existing “pay-and-chase” method of looking for improper payments after they’ve already been made.
Wall Street investors rebounded from the jolt delivered by the Centers for Medicare & Medicaid Services last week, regaining most of the value lost after the agency announced stiffer rules for its coverage of some medical procedures.
The new pre-reimbursement review program will ask doctors to provide up-front justification for certain medical equipment and types of claims. Set to launch in 11 states next month, it will flip the reimbursement system from the agency’s existing “pay-and-chase” method of looking for improper payments after they’ve already been made.
C.R. Bard Inc. (NYSE:BCR) plans to cut 50 jobs from its Queensbury, N.Y.-based manufacturing plant.
The 50 positions could be relocated outside the U.S., according to the Glen Falls, N.Y.-based Post Star. That would leave the Queensbury plant with roughly 770 employees.
Abiomed (NSDQ:ABMD) shares hit $20.25 apiece yesterday, their highest mark in 52 weeks, as the company touted more positive study results for its flagship Impella heart pump.
ABMD shares closed yesterday at $20.14, up 6.2 percent on a day of widespread gains on Wall Street. The Dow Jones Industrial Average gained 4.2 percent yesterday, the S&P 500 closed up 4.3 percent and the Dow Jones medical device index rose 4.8 percent.
TrapEase permanent vena cava filter
A new study reported a high fracture rate among permanent inferior vena cava filters made by Cordis Corp., a device-making arm of Johnson & Johnson (NYSE:JNJ).
In a Japanese study of 20 patients with Cordis’ TrapEase IVC filter, the devices fractured in half the patients at 50 months.
Group purchasing organization goliath Premier inked two new agreements for electrophysiology equipment and Cure Surgicals signed a supply deal for surgical aspirators and bone cutters.
Premier healthcare alliance signed agreements with C.R. Bard (NYSE:BCR) subsidiary Bard Electrophysiology Products and Natick, Mass.-based Boston Scientific (NYSE:BSX).
Shares of Olympus Corp. (TYO:7733) regained more than 17 percent over the weekend after the Tokyo stock exchange indicated it might not de-list the world’s largest endoscope maker, brought low by a scheme to hide its losses with buyouts.
